1. |
Ropinirole a good option in early Parkinson's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
ACE inhibitors and AIIRAs: beyond their effects on BP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 3-4
Jo Dalton,
Preview
|
|
摘要:
'Blood pressure can be measured and needs to be treated, but we need to be smarter than this in our future approach to cardiovascular disease',said Professor Jay Cohn from the University of Minnesota, Minneapolis, US, at the 15th Scientific Meeting of the American Society of Hypertension [New York, US; May 2000]. He was referring to the fact that hypertension is not simply a disease of numbers but rather, a syndrome of risk factors, all of which contribute to the development of cardiovascular disease in patients with hypertension. Studies have demonstrated that, independently of its effects on BP, blockade of the renin-angiotensin system may have beneficial effects on other components of the hypertension syndrome. Preliminary results from the Study to Evaluate Carotid Ultrasound Changes with Ramipril and Vitamin E (SECURE) were discussed at the meeting, as were the designs of the next generation of potential landmark trials involving angiotensin II receptor antagonists (AIIRAs).
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
Nefazodone best value new blues-buster? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 7-8
Amanda Cameron,
Preview
|
|
摘要:
Newer antidepressants have one major advantage over their older tricyclic cousins - namely, they are generally better tolerated. And, despite higher upfront costs, the newer agents have been associated with lower total depression treatment costs than the tricyclics. But when it comes to choosing between the range of newer antidepressants available, there is very little research comparing the relative economic benefits of these agents. Now, however, a new study has revealed that nefazodone has the lowest depression-related treatment costs of 6 new antidepressants.1The study was presented at a poster session of the 5th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 2000].
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
Disulfiram may inhibit P-gp-mediated drug resistance |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1245,
2000,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|